guidelin
manag
communityacquir
pneumonia
cap
adult
demonstr
decreas
morbid
mortal
rate
guidelin
creat
assist
clinician
care
child
cap
repres
approach
diagnosi
therapi
consider
variat
among
children
clinic
cours
pediatr
cap
even
infect
caus
pathogen
goal
guidelin
decreas
morbid
mortal
rate
cap
children
present
recommend
clinic
manag
appli
individu
case
deem
appropri
treat
clinician
document
design
provid
guidanc
care
otherwis
healthi
infant
children
address
practic
question
diagnosi
manag
cap
evalu
outpati
offic
urgent
care
clinic
emerg
depart
inpati
set
unit
state
manag
neonat
young
infant
first
month
immunocompromis
children
children
receiv
home
mechan
ventil
children
chronic
condit
underli
lung
diseas
cystic
fibrosi
beyond
scope
guidelin
discuss
summar
recommend
made
new
pediatr
cap
guidelin
panel
follow
process
use
develop
infecti
diseas
societi
america
idsa
guidelin
includ
systemat
weight
qualiti
evid
grade
recommend
tabl
detail
descript
method
background
evid
summari
support
recommend
found
full
text
guidelin
blood
cultur
outpati
blood
cultur
inpati
followup
blood
cultur
sputum
gram
stain
cultur
urinari
antigen
detect
test
complet
blood
cell
count
acutephas
reactant
puls
oximetri
initi
chest
radiograph
outpati
initi
chest
radiograph
inpati
followup
chest
radiograph
outpati
inpati
pneumonia
singl
greatest
caus
death
children
worldwid
year
million
children
younger
year
die
pneumonia
repres
death
children
within
age
group
although
difficult
quantifi
believ
million
case
pneumonia
occur
children
everi
year
worldwid
develop
world
annual
incid
pneumonia
case
per
children
year
old
unit
state
outpati
visit
rate
cap
defin
use
intern
classif
diseas
ninth
revis
clinic
modif
diagnosi
code
report
nation
ambulatori
medic
care
survey
nation
hospit
ambulatori
medic
care
survey
identifi
rate
rang
per
children
year
old
per
children
year
old
rate
hospit
cap
children
age
year
use
data
healthcar
cost
util
project
kid
inpati
databas
also
base
discharg
diagnosi
code
per
infant
year
old
highest
rate
hospit
per
wherea
children
year
lowest
rate
per
data
center
diseas
control
prevent
cdc
document
infant
children
year
old
die
unit
state
result
pneumonia
lower
respiratori
tract
infect
report
incid
pneumonia
children
pathogen
specif
gener
diagnosi
vari
across
publish
studi
base
definit
use
test
perform
goal
investig
cap
children
unit
state
focu
guidelin
defin
simpli
presenc
sign
symptom
pneumonia
previous
healthi
child
caus
infect
acquir
outsid
hospit
howev
pneumonia
definit
also
design
sensit
epidemiolog
consider
eg
fever
cough
specif
defin
govern
regulatori
agenc
approv
antimicrobi
treat
pneumonia
eg
clinic
symptom
sign
combin
radiolog
document
microbiolog
confirm
pneumonia
broadli
defin
lower
respiratori
tract
infect
lrti
may
also
defin
way
clinic
orient
assist
practition
diagnosi
manag
mani
pathogen
respons
cap
children
promin
virus
bacteria
investig
use
varieti
laboratori
test
establish
microbi
etiolog
cap
exampl
diagnosi
pneumococc
pneumonia
base
posit
cultur
blood
antibodi
respons
antigen
detect
nucleic
acid
detect
test
differ
sensit
specif
posit
neg
predict
valu
depend
preval
pathogen
time
test
therefor
compar
etiolog
pneumonia
publish
studi
challeng
recent
investig
use
varieti
sensit
molecular
techniqu
includ
nucleic
acid
detect
particularli
viral
identif
mani
children
lrti
diagnost
test
may
identifi
pathogen
includ
combin
virus
bacteria
make
difficult
determin
signific
singl
pathogen
furthermor
uniqu
pediatr
develop
immun
system
agerel
exposur
result
infect
caus
differ
bacteri
viral
pathogen
requir
incid
cap
potenti
pathogen
defin
separ
age
group
advent
polysaccharideprotein
conjug
vaccin
h
influenza
type
b
serotyp
pneumonia
pneumococc
conjug
vaccin
dramat
decreas
incid
infect
includ
cap
caus
bacteria
newer
vaccin
protect
greater
number
pneumococc
serotyp
variou
stage
clinic
develop
newli
licens
pneumococc
conjug
vaccin
avail
unit
state
report
epidemiolog
investig
etiolog
cap
widespread
use
vaccin
cite
pneumonia
common
document
bacteri
pathogen
occur
children
investig
studi
viral
etiolog
cap
document
children
younger
year
contrast
investig
older
children
year
clinic
radiograph
evid
pneumonia
document
much
lower
percentag
viral
pathogen
viral
pathogen
rsv
consist
frequent
detect
repres
identifi
pathogen
younger
year
rare
identifi
older
children
cap
less
frequent
detect
adenovirus
bocaviru
human
metapneumoviru
influenza
b
virus
parainfluenza
virus
coronavirus
rhinoviru
epidemiolog
investig
hospit
children
cap
document
simultan
infect
virus
epidemiolog
studi
assess
viral
bacteri
pathogen
report
bacteri
pathogen
isol
children
cap
inpati
studi
enrol
serious
ill
children
often
document
higher
rate
bacteri
infect
compar
outpati
studi
pathogen
respons
atyp
pneumonia
identifi
children
studi
pneumonia
often
identifi
older
children
c
pneumonia
infant
atyp
pneumonia
caus
mycoplasma
characterist
slowli
progress
malais
sore
throat
lowgrad
fever
cough
develop
day
contrast
adult
pneumonia
legionella
sp
rare
identifi
children
although
cap
caus
mycobacterium
tuberculosi
nontubercul
mycobacteria
welldocu
incid
seriou
infect
unit
state
far
less
viral
bacteri
cap
often
link
highrisk
exposur
likewis
fungal
pneumonia
normal
host
caus
histoplasma
coccidioid
blastomyc
cryptococcu
uncommon
epidemiolog
studi
children
fungal
pneumonia
identifi
mycobacteri
fungal
pneumonia
address
guidelin
child
infant
cap
requir
hospit
ii
child
cap
admit
intens
care
unit
icu
unit
continu
cardiorespiratori
monitor
iii
diagnost
laboratori
imag
test
use
child
suspect
cap
clinic
hospit
ward
set
iv
addit
diagnost
test
use
child
sever
lifethreaten
cap
v
antiinfect
therapi
provid
child
suspect
cap
outpati
inpati
set
vi
resist
antimicrobi
minim
vii
appropri
durat
antimicrobi
therapi
cap
viii
clinician
follow
child
cap
expect
respons
therapi
ix
parapneumon
effus
identifi
x
factor
import
determin
whether
drainag
parapneumon
effus
requir
xi
laboratori
test
perform
pleural
fluid
xii
drainag
option
parapneumon
effus
xiii
vat
open
surgic
decort
consid
patient
chest
tube
drainag
without
fibrinolyt
therapi
xiv
chest
tube
remov
either
primari
drainag
vat
xv
antibiot
therapi
durat
indic
treatment
parapneumon
effusionempyema
see
also
section
antiinfect
treatment
xvi
appropri
manag
child
respond
treatment
cap
xvii
nonrespond
pulmonari
abscess
necrot
pneumonia
manag
xviii
hospit
child
cap
safe
discharg
xix
parenter
outpati
therapi
indic
contrast
oral
stepdown
therapi
xx
pediatr
cap
prevent
mani
aspect
clinic
manag
cap
complic
tabl
clinic
practic
recommend
regard
daili
manag
children
hospit
cap
includ
intraven
fluid
manag
techniqu
deliveri
monitor
oxygen
manag
respiratori
tract
secret
well
import
econom
social
issu
beyond
scope
first
edit
pediatr
cap
guidelin
address
panel
practic
guidelin
systemat
develop
statement
assist
practition
patient
make
decis
appropri
health
care
specif
clinic
circumst
attribut
good
guidelin
includ
valid
reliabl
reproduc
clinic
applic
clinic
flexibl
clariti
multidisciplinari
process
review
evid
document
pediatr
infecti
diseas
societi
pid
idsa
standard
practic
guidelin
committe
spgc
conven
expert
pediatr
cap
field
commun
pediatr
public
health
pediatr
subspecialti
critic
care
medicin
emerg
medicin
hospit
medicin
infecti
diseas
pulmonolog
surgeri
panel
particip
includ
repres
follow
collabor
organ
american
academi
pediatr
aap
american
colleg
emerg
physician
american
thorac
section
societi
hospit
medicin
societi
critic
care
medicin
american
pediatr
surgic
associ
addit
expert
consult
diagnost
microbiolog
includ
virolog
intervent
radiolog
ask
review
provid
feedback
draft
guidelin
clinic
practic
guidelin
develop
idsa
need
guidelin
pediatr
cap
demonstr
goal
guidelin
similar
cap
adult
clinic
question
develop
write
group
approv
idsa
spgc
computer
literatur
search
nation
librari
medicin
pubm
databas
perform
identifi
data
publish
may
although
recent
articl
particular
relev
guidelin
includ
relev
abstract
recent
profession
meet
exist
guidelin
pediatr
cap
also
identifi
collect
review
idsa
clinic
practic
guidelin
initi
octob
expert
panel
employ
grade
grade
recommend
assess
develop
evalu
method
assign
strength
recommend
qualiti
evid
recommend
see
tabl
appli
guidelin
write
group
believ
circumst
qualiti
evid
low
low
like
situat
even
strong
recommend
may
appli
specif
subgroup
within
popul
intend
recommend
mani
condit
lack
moder
highqual
evid
clinic
judgment
still
play
import
role
manag
unfortun
mani
situat
current
prospect
collect
highqual
evid
avail
highlight
critic
need
investig
order
establish
solid
basi
futur
recommend
expert
panel
met
initi
occas
via
teleconfer
complet
organiz
work
guidelin
person
annual
meet
idsa
within
panel
subgroup
form
clinic
question
subgroup
review
literatur
relev
clinic
question
respons
draft
recommend
evid
summari
assign
section
draft
circul
within
panel
commentari
discuss
addit
confer
call
facetofac
meet
held
conjunct
pediatr
academ
societi
meet
refin
recommend
evid
summari
occur
subsequ
teleconfer
call
member
panel
particip
prepar
review
draft
guidelin
feedback
solicit
extern
peer
review
organ
repres
expert
panel
guidelin
endors
aap
american
colleg
emerg
physician
american
societi
microbiolog
american
thorac
societi
societi
hospit
medicin
societi
critic
care
medicin
guidelin
review
approv
pid
clinic
affair
committe
idsa
spgc
council
pid
board
director
idsa
dissemin
member
expert
panel
compli
idsa
polici
conflict
interest
requir
disclosur
financi
interest
might
constru
constitut
actual
potenti
appar
conflict
given
idsa
conflict
interest
disclosur
statement
ask
identifi
tie
compani
develop
product
might
affect
promulg
guidelin
inform
request
regard
employ
consult
stock
ownership
honoraria
research
fund
expert
testimoni
membership
compani
advisori
committe
panel
made
decis
casebycas
basi
whether
individu
role
limit
result
conflict
potenti
conflict
list
acknowledg
section
guidelin
primarili
design
address
infant
children
live
unit
state
reason
access
healthcar
histori
present
examin
child
major
determin
sever
ill
appropri
level
care
respect
outpati
inpati
manag
physician
overal
assess
child
statu
time
examin
anticip
clinic
cours
determin
site
care
howev
guidelin
write
group
recogn
data
chest
radiographi
puls
oximetri
laboratori
studi
use
variabl
practition
support
medic
decis
make
guidelin
defin
simpl
pneumonia
either
bronchopneumonia
primari
involv
airway
surround
interstitium
lobar
pneumonia
involv
singl
lobe
complic
pneumonia
defin
pulmonari
parenchym
infect
complic
parapneumon
effus
multilobar
diseas
abscess
caviti
necrot
pneumonia
empyema
pneumothorax
bronchopleur
fistula
pneumonia
complic
bacterem
diseas
includ
site
infect
resourcepoor
region
world
world
health
organ
defin
pneumonia
primarili
cough
difficult
breath
ageadjust
tachypnea
age
month
year
year
breathsmin
furthermor
sever
pneumonia
defin
cough
difficulti
breath
plu
one
follow
lower
chest
indraw
nasal
flare
grunt
sever
pneumonia
defin
cough
difficulti
breath
plu
one
follow
cyanosi
sever
respiratori
distress
inabl
drink
vomit
everyth
lethargyunconsciousnessconvuls
definit
variou
level
sever
studi
valid
intervent
level
sever
well
character
children
live
resourcerich
area
world
sever
end
spectrum
clinic
present
expert
profession
societi
recommend
child
infant
respiratori
distress
tabl
admit
hospit
manag
compar
studi
develop
world
evalu
outcom
children
variou
degre
respiratori
distress
manag
outpati
compar
manag
inpati
publish
toxic
appear
well
defin
repres
compon
provid
tabl
univers
accept
indic
admiss
hospit
past
decad
mani
consensu
guidelin
clinic
decis
rule
propos
adult
cap
multipl
adult
studi
describ
score
system
demonstr
use
predict
adult
hospit
adult
requir
intens
care
unfortun
score
system
valid
children
consid
pediatr
comorbid
condit
development
stage
psychosoci
factor
influenc
treat
clinician
decis
site
treatment
pediatr
patient
cap
valid
score
system
predict
children
pneumonia
hospit
exist
score
predict
mortal
critic
ill
children
hospit
pediatr
icu
exist
decad
sever
ill
score
built
upon
multipl
logist
regress
model
pediatr
risk
mortal
score
pediatr
index
mortal
predict
risk
death
children
icu
set
may
facilit
outcom
predict
icu
reliabl
help
clinician
discrimin
sever
ill
less
acut
ill
child
therebi
limit
util
levelofcar
decis
make
directli
relev
evalu
sever
diseas
cap
simpl
measur
oxygen
puls
oximetri
hypoxemia
well
establish
risk
factor
poor
outcom
children
infant
type
diseas
especi
respiratori
diseas
use
puls
oximetri
detect
hypoxemia
confirm
relationship
guidelin
clinic
decis
rule
usual
recommend
puls
oximetri
patient
pneumonia
develop
world
pediatr
patient
nonsever
pneumonia
defin
puls
oximetr
measur
initi
visit
document
predict
failur
outpati
oral
amoxicillin
treatment
adult
hypoxemia
indic
respiratori
failur
requir
icu
admiss
patient
pneumonia
also
independ
associ
shortterm
mortal
widespread
agreement
exist
admiss
indic
previous
healthi
child
cap
oxygen
satur
room
air
sea
level
although
would
hospit
children
oxygen
satur
high
higher
altitud
lower
oxygen
satur
may
appropri
defin
respiratori
failur
demonstr
bolivia
clinic
surrog
exist
adequ
oxygen
convers
hypoxemia
sever
pneumonia
child
infant
overal
gener
assess
abil
consol
usual
denot
normal
oxygen
moder
sever
alter
gener
statu
independ
risk
factor
death
children
hospit
develop
world
acut
lrti
although
cyanosi
may
sometim
difficult
detect
presenc
denot
sever
hypoxemia
systemat
review
publish
studi
primarili
develop
world
found
central
cyanosi
higher
specif
predict
hypoxemia
children
sign
tachypnea
nonspecif
clinic
sign
may
repres
marker
respiratori
distress
andor
hypoxemia
rapid
breath
perceiv
mother
statist
associ
hypoxemia
studi
children
pneumonia
increas
agespecif
respiratori
rate
tachypnea
link
treatment
failur
children
sever
pneumonia
develop
world
although
tachypnea
infant
pneumonia
may
correl
presenc
hypoxemia
tachypnea
may
also
caus
fever
dehydr
concurr
metabol
acidosi
studi
pediatr
emerg
depart
boston
children
year
old
undergo
chest
radiographi
possibl
pneumonia
respiratori
rate
document
pneumonia
differ
significantli
children
without
pneumonia
howev
children
whodefin
tachypnea
confirm
pneumonia
compar
without
tachypnea
retract
grunt
also
found
indic
increas
sever
lrti
children
hospit
argentina
retract
whether
intercost
suprastern
subcost
indic
greater
sever
pneumonia
nasal
flare
head
bob
also
statist
associ
hypoxemia
dehydr
vomit
inabl
take
oral
medic
addit
consider
hospit
children
oral
outpati
antimicrobi
therapi
attempt
unsuccess
demonstr
new
progress
respiratori
distress
tabl
often
requir
hospit
furthermor
psychosoci
concern
noncompli
therapi
lack
reliabl
followup
reason
may
warrant
admiss
studi
unit
state
canada
found
children
infant
pneumonia
like
hospit
lower
socioeconom
statu
may
attribut
part
nonmed
issu
includ
inaccess
adequ
outpati
servic
children
pneumonia
caus
camrsa
describ
case
seri
high
incid
necrot
pneumonia
frequent
requir
icu
admiss
retrospect
studi
adult
children
pantonvalentin
aureu
cap
requir
mechan
ventil
high
suspicion
document
camrsa
caus
organ
clinician
hospit
child
treatment
parenter
antimicrobi
therapi
close
observ
even
respiratori
symptom
sever
time
initi
evalu
presenc
signific
comorbid
condit
also
risk
factor
develop
pneumonia
presenc
pneumonia
often
result
worsen
underli
condit
dalla
texa
children
admit
cap
comorbid
condit
includ
reactiv
airway
diseas
genet
syndrom
neurocognit
disord
tan
colleagu
pediatr
tertiari
care
center
found
children
hospit
pneumococc
pneumonia
underli
comorbid
condit
also
includ
immunolog
disord
hematolog
cardiac
chronic
pulmonari
condit
children
comorbid
condit
influenza
infect
like
requir
hospit
otherwis
healthi
children
although
children
chronic
condit
may
greater
risk
pneumonia
condit
extrem
divers
specif
manag
issu
comorbid
condit
address
guidelin
young
age
addit
risk
factor
sever
pneumonia
need
hospit
incid
pneumonia
risk
sever
pneumonia
greater
infant
young
children
attack
rate
per
infant
age
month
per
preschoolag
children
year
per
schoolag
children
year
per
children
year
old
furthermor
infant
young
children
tend
sever
pneumonia
greater
need
hospit
higher
risk
respiratori
failur
one
independ
risk
factor
death
children
hospit
acut
respiratori
tract
infect
central
african
republ
age
month
howev
malnutrit
may
also
contribut
sever
diseas
develop
world
temper
conclus
mortal
age
group
respiratori
tract
diseas
alon
clinic
tool
design
predict
child
sever
pneumonia
would
failur
oral
antimicrobi
therapi
develop
world
found
age
child
one
import
clinic
predictor
highli
signific
month
age
develop
world
prospect
collect
data
publish
document
cutoff
age
hospit
necessari
improv
outcom
unit
state
young
infant
month
age
cap
gener
admit
hospit
initi
manag
given
increas
risk
morbid
admiss
infant
month
age
suspect
bacteri
cap
also
prudent
child
requir
hospit
cap
clinician
need
consid
capabl
accept
facil
unit
variat
level
monitor
skill
bedsid
provid
nurs
respiratori
therapist
physician
influenc
decis
effect
monitor
treat
ill
child
appropri
placement
ill
child
increas
work
breath
tachypnea
hypoxemia
optim
use
icu
gener
care
area
resourc
consult
specialist
pediatr
critic
care
medicin
recommend
concern
regard
appropri
patient
placement
base
sever
diseas
tabl
iculevel
care
typic
requir
children
cap
howev
studi
dalla
texa
children
hospit
cap
requir
mechan
ventil
children
cap
die
although
almost
onethird
comorbid
condit
greater
proport
mix
bacteri
viral
infect
requir
mechan
ventil
mortal
subgroup
children
hospit
cap
hypoxemia
present
mani
children
cap
mani
case
lowflow
supplement
oxygen
provid
nasal
cannula
face
mask
suffic
restor
oxygen
satur
manag
hospit
ward
children
requir
fraction
inspir
oxygen
maintain
satur
care
unit
capabl
continu
cardiorespiratori
monitor
rapid
respons
clinic
situat
worsen
sign
respiratori
distress
potenti
respiratori
insuffici
includ
increas
work
breath
evidenc
retract
suprastern
subcost
intercost
nasal
flare
use
accessori
muscl
recurr
apnea
grunt
grunt
present
sign
sever
diseas
impend
respiratori
failur
oxygen
satur
puls
oximetri
usual
monitor
continu
child
increas
work
breath
signific
distress
particularli
decreas
level
activ
agit
child
overal
clinic
appear
behavior
may
predict
much
sever
ill
score
avail
exclus
use
sever
ill
score
hospit
admiss
reliabl
provid
clinician
enough
data
determin
need
iculevel
care
arteri
oxygen
pressur
ratio
provid
indic
degre
respiratori
insuffici
impair
oxygen
diffus
conjunct
clinic
examin
enhanc
determin
ill
sever
test
requir
arteri
blood
ga
determin
use
warrant
evalu
sever
cap
interpret
ratio
physician
experienc
treat
children
respiratori
failur
sever
pneumonia
need
icu
admiss
may
defin
part
etiolog
retrospect
review
children
admit
pediatr
tertiari
care
center
invas
pneumococc
infect
concurr
posit
viral
studi
influenza
rhinoviru
adenoviru
rsv
admit
pediatr
icu
frequent
found
longer
pediatr
icu
stay
retrospect
case
seri
pediatr
patient
camrsa
pneumonia
shown
high
incid
necrot
pneumonia
need
icu
care
high
associ
mortal
blood
cultur
outpati
blood
cultur
inpati
followup
blood
cultur
sputum
gram
stain
cultur
urinari
antigen
detect
test
complet
blood
cell
count
acutephas
reactant
puls
oximetri
initi
chest
radiograph
outpati
initi
chest
radiograph
inpati
followup
chest
radiograph
microbiolog
test
recommend
intend
identifi
pathogen
narrowspectrum
antimicrobi
therapi
direct
specif
bacterium
viru
initi
narrowest
treatment
possibl
consid
ideal
often
lead
less
antimicrobi
pressur
select
resist
fewer
advers
drug
reaction
reduc
cost
blood
cultur
outpati
blood
cultur
posit
provid
document
caus
agent
import
epidemiolog
data
howev
blood
cultur
obtain
fulli
immun
children
nonsever
pneumonia
steril
furthermor
cultur
blood
fail
detect
mani
import
caus
childhood
cap
includ
pneumonia
viral
pathogen
therefor
blood
cultur
help
defin
etiolog
small
proport
children
cap
treat
outpati
current
studi
blood
cultur
outpati
evalu
children
cap
conduct
licensur
h
influenza
type
b
conjug
vaccin
licensur
studi
blood
cultur
posit
pathogen
bacteria
patient
pneumonia
well
enough
manag
outpati
set
random
trial
blood
cultur
posit
vaccin
recipi
develop
pneumonia
rate
detect
trueposit
case
bacteremia
children
cap
manag
outpati
set
lower
rate
falseposit
blood
cultur
report
studi
childhood
cap
studi
evalu
role
blood
cultur
emerg
depart
evalu
young
children
fever
known
extent
relationship
attribut
effect
precultur
antibiot
inadequ
blood
cultur
techniqu
insuffici
blood
volum
cultur
combin
factor
blood
volum
sampl
bacteri
cultur
infant
children
less
adult
publish
seri
use
fdaapprov
pediatr
blood
cultur
diagnost
test
optim
ml
blood
children
includ
data
analys
blood
volum
low
ml
blood
cultur
inpati
contrast
evalu
outpati
blood
cultur
frequent
posit
pathogen
bacteria
children
requir
hospit
cap
report
rate
rang
studi
howev
investig
utah
use
stringent
criteria
bacteri
cap
report
blood
cultur
posit
patient
requir
hospit
cap
half
organ
identifi
pneumonia
serotyp
serotyp
includ
present
formul
blood
cultur
routin
perform
children
hospit
cap
prior
studi
like
blood
cultur
perform
disproportion
children
greater
ill
sever
thu
prior
studi
may
overestim
true
rate
bacteremia
children
hospit
uncompl
cap
among
patient
pneumonia
complic
parapneumon
effus
rate
bacteremia
also
vari
rang
preval
bacteremia
confid
interv
among
children
pneumoniaassoci
complic
includ
sepsi
organ
dysfunct
despit
low
overal
yield
blood
cultur
patient
requir
hospit
knowledg
caus
organ
provid
inform
allow
treat
physician
target
antibiot
therapi
caus
agent
culturedirect
antimicrobi
select
may
associ
improv
clinic
outcom
minor
pediatr
case
shown
studi
adult
cap
contrast
adult
cap
posit
blood
cultur
infrequ
affect
clinic
manag
posit
blood
cultur
result
narrow
broaden
therapi
patient
posit
cultur
among
children
blood
cultur
obtain
howev
overal
impact
blood
cultur
clinic
manag
may
small
low
preval
bacteremia
addit
worth
note
epidemiolog
data
deriv
blood
cultur
result
essenti
creat
evidencebas
pneumococc
vaccin
polici
unit
state
blood
cultur
posit
contamin
nonpathogen
bacteria
ie
falseposit
cultur
result
may
lead
unnecessari
broaden
antibiot
therapi
may
difficult
determin
whether
broader
therapi
contribut
patient
clinic
improv
led
prolong
inappropri
treatment
cours
costeffect
obtain
blood
cultur
children
hospit
cap
known
sputum
gram
stain
cultur
gram
stain
cultur
expector
sputum
recommend
adult
hospit
cap
test
infrequ
perform
children
cap
children
alway
provid
adequ
specimen
test
gram
stain
cultur
expector
sputum
attempt
older
children
adolesc
sever
diseas
includ
inpati
outpati
therapi
fail
better
diagnost
test
need
particularli
children
nonsever
pneumonia
benefit
aggress
invas
diagnost
procedur
may
worth
risk
child
urinari
antigen
detect
test
urinari
antigen
test
detect
pneumonia
correl
well
sputum
cultur
pneumonia
adult
therefor
antigen
detect
routin
use
diagnos
pneumococc
pneumonia
adult
children
urin
antigen
test
posit
lobar
pneumonia
howev
etiolog
pneumonia
could
confirm
relev
find
clear
even
greater
concern
posit
result
occur
febril
children
without
evid
invas
pneumococc
diseas
clear
whether
falseposit
result
attribut
pneumococc
nasopharyng
colon
trueposit
result
context
earli
pulmonari
diseas
produc
characterist
radiograph
find
whether
associ
spontan
resolv
pneumococc
infect
dowel
et
al
found
signific
differ
proport
posit
pneumococc
urinari
antigen
result
children
pneumonia
compar
children
dermat
diarrhea
howev
posit
result
strongli
associ
pneumococc
colon
studi
also
suggest
posit
result
attribut
nasopharyng
colon
pneumonia
children
posit
result
pneumococc
urinari
antigen
test
reliabl
distinguish
children
pneumococc
pneumonia
mere
colon
absenc
true
refer
standard
insuffici
inform
neg
predict
valu
test
recommend
use
exclud
pneumococc
diseas
substanti
evid
risk
seriou
bacteri
infect
low
children
laboratoryconfirm
viral
infect
howev
diffus
lower
respiratori
tract
inflamm
induc
viral
respiratori
tract
infect
predispos
bacteri
superinfect
make
difficult
exclud
concurr
bacteri
pneumonia
certainti
children
laboratoryconfirm
viral
infect
viral
bacteri
coinfect
detect
children
pneumonia
evalu
tertiarycar
children
hospit
random
clinic
trial
prospect
studi
rapid
influenza
test
demonstr
signific
reduct
ancillari
test
antibiot
use
among
children
evalu
emerg
depart
influenza
season
bonner
et
al
enrol
patient
age
month
year
fever
influenzalik
ill
rapid
influenza
test
perform
nasopharyng
specimen
patient
posit
influenza
patient
random
treat
physician
either
provid
provid
result
influenza
test
antibiot
prescrib
patient
physician
awar
posit
influenza
test
result
compar
patient
physician
awar
result
similar
reduct
note
perform
chest
radiographi
ancillari
test
patient
lobar
pneumonia
esposito
et
al
random
children
present
clinic
influenzalik
ill
rapid
influenza
test
test
children
test
posit
antibiot
prescrib
influenzaposit
compar
influenzaneg
patient
random
test
given
antibiot
signific
differ
note
perform
chest
radiograph
group
retrospect
cohort
studi
hospit
adult
laboratoryconfirm
influenza
infect
posit
rapid
influenza
test
result
associ
higher
odd
discontinu
withhold
antibiot
therapi
compar
influenzaposit
patient
whose
diagnosi
delay
posit
pcr
result
readili
avail
doan
et
al
conduct
openlabel
random
control
trial
children
month
age
random
receiv
multivir
rapid
diagnost
test
direct
immunofluoresc
assay
ifa
n
routin
care
n
least
one
viru
detect
patient
random
viral
test
differ
antibiot
prescrib
perform
chest
radiographi
ancillari
test
virusposit
virusneg
untest
patient
statist
signific
howev
patient
undergo
viral
test
less
like
receiv
antibiot
subsequ
see
primari
care
physician
ill
within
week
discharg
emerg
depart
retrospect
review
byington
colleagu
document
signific
decreas
antibiot
prescrib
respect
inpati
intraven
therapi
oral
antibiot
therapi
discharg
hospit
children
test
posit
rsv
parainfluenza
adenoviru
compar
test
neg
although
posit
test
viral
pathogen
help
sensit
specif
rapid
viral
test
falseneg
falseposit
test
occur
influenza
sensit
type
test
vari
method
sampl
techniqu
rapid
test
may
also
vari
strain
influenza
circul
given
year
exampl
sensit
rapid
influenza
test
pandem
poor
compar
perform
test
season
influenza
children
influenzalik
ill
commun
document
influenza
viru
circul
neg
rapid
influenza
viru
test
child
cap
symptom
compat
influenza
may
reflect
inaccuraci
test
rather
reliabl
exclud
influenza
viru
pathogen
children
influenza
particularli
requir
mechan
ventil
initi
result
nasopharyng
test
influenza
may
neg
even
reversetranscriptas
pcr
techniqu
mani
factor
includ
poorqual
specimen
sampl
upper
rather
lower
respiratori
tract
prolong
durat
ill
onset
specimen
collect
multipl
specimen
multipl
day
may
requir
diagnosi
earli
influenza
antivir
therapi
provid
greatest
benefit
child
clinician
wait
start
empir
antivir
therapi
obtain
respiratori
tract
sampl
diagnosi
children
viral
lrti
may
also
associ
bacteri
lrti
studi
serious
ill
ventil
infant
document
rsv
cap
levin
et
al
found
specimen
suggest
concomit
bacteri
infect
base
tracheal
aspir
cultur
conclud
patient
literatur
review
evid
bacteri
pneumonia
otherwis
lowrisk
infant
rsv
present
respiratori
failur
present
use
empir
antibiot
hour
pend
cultur
result
may
justifi
concomit
bacteri
infect
exclud
howev
infant
respiratori
failur
find
suggest
bacteri
coinfect
care
process
model
potenti
decreas
inappropri
antibiot
use
discourag
use
children
document
posit
rapid
test
respiratori
viru
precis
role
test
treat
pneumonia
lrti
children
well
defin
highqual
data
natur
histori
diseas
impact
treatment
avail
younger
children
particular
decis
regard
test
made
difficult
uncertainti
regard
extent
treatment
confirm
pneumonia
infect
improv
clinic
outcom
popul
see
evid
summari
recommend
treatment
cap
children
import
minim
unnecessari
prescrib
macrolid
therapi
may
inadequ
treatment
pneumonia
offer
best
care
children
cap
caus
pneumonia
test
pneumonia
may
use
pretest
probabl
pneumonia
infect
intermedi
high
age
one
begin
strongli
consid
pneumonia
caus
cap
well
defin
pneumonia
increasingli
diagnos
serolog
caus
lrti
young
children
test
may
necessari
children
low
likelihood
pneumonia
infect
eg
younger
children
symptom
compat
primari
viral
upper
respiratori
tract
infect
posit
predict
valu
posit
test
may
modest
ie
falseposit
result
occur
test
may
use
guid
decis
regard
empir
antibiot
therapi
schoolag
children
adolesc
find
consist
classic
pneumonia
infect
situat
posit
test
result
pneumonia
may
warrant
treatment
wherea
neg
result
make
diagnosi
pneumonia
pneumonia
unlik
epidemiolog
aspect
pneumonia
infect
commonli
avail
test
summar
varieti
test
exist
detect
pneumonia
infect
includ
cultur
cold
agglutin
antibodi
serolog
molecularbas
method
pcr
assay
differ
perform
characterist
sensit
specif
posit
neg
predict
valu
complex
nutrit
requir
slow
growth
pneumonia
cultur
media
make
identif
impract
laboratori
addit
result
cultur
pneumonia
avail
clinic
relev
time
frame
presenc
coldreact
antibodi
red
blood
cell
serum
patient
primari
atyp
pneumonia
well
known
cold
agglutinin
titer
present
time
acut
ill
adult
pneumonia
due
pneumonia
test
less
well
studi
children
accuraci
detect
respiratori
infect
due
pneumonia
known
specif
titer
low
varieti
respiratori
tract
pathogen
provok
modest
increas
cold
agglutinin
perform
cold
agglutinin
test
bedsid
lack
rigor
standard
high
sensit
specif
reproduc
current
expect
medic
diagnost
recommend
set
serolog
method
includ
complement
fixat
enzymelink
immunosorb
assay
elisa
rapid
enzym
immunoassay
card
enzym
assay
less
time
consum
thu
larg
replac
complement
fixat
test
laboratori
set
detect
immunoglobulin
ig
rapid
serolog
test
typic
result
avail
within
min
immunocard
rapid
igm
test
meridian
bioscienc
compar
serolog
test
pcr
alexand
et
al
studi
specimen
submit
clinic
laboratori
pneumonia
serolog
test
compar
pneumonia
igmspecif
assay
ifa
elisa
standard
complement
fixat
procedur
immunocard
sensit
rang
compar
elisa
compar
complement
fixat
inconsist
result
resolv
use
ifa
refer
standard
immunocard
specif
rang
compar
igmspecif
elisa
compar
igmspecif
ifa
inconsist
resolv
use
medic
record
review
result
similar
subsequ
studi
children
refer
pneumonia
test
howev
specif
igm
detect
describ
outbreak
pneumonia
pneumonia
children
year
age
year
age
compar
case
definit
refer
standard
diagnosi
combin
iggigm
assay
remel
thermo
fisher
scientif
assess
outbreak
higher
specif
children
year
age
lower
sensit
compar
igm
detect
igm
assay
platelia
igm
captur
sanofi
diagnost
appear
sensit
pcr
detect
pneumonia
cap
children
direct
comparison
studi
use
pcr
difficult
specimen
obtain
differ
site
eg
nasal
wash
nasopharyng
swab
throat
sputum
use
differ
primer
set
amplif
techniqu
pcrbase
test
neither
readili
avail
practic
offic
emerg
depart
commun
hospit
set
use
current
avail
test
system
summari
believ
test
mycoplasma
infect
import
optim
use
macrolid
children
howev
singl
current
avail
test
offer
sensit
specif
desir
clinic
relev
time
frame
therefor
clinician
knowledg
regard
perform
characterist
test
offer
local
laboratori
none
mani
diagnost
assay
use
worldwid
identifi
c
pneumonia
receiv
approv
us
food
drug
administr
clinic
use
recommend
standard
approach
cultur
pcr
test
serolog
immunohistochemistri
publish
cdc
canadian
laboratori
centr
diseas
control
lcdc
serolog
primari
mean
clinic
diagnost
test
c
pneumonia
widespread
avail
rel
simplic
howev
mani
avail
assay
includ
complement
fixat
whole
inclus
fluoresc
variou
enzym
immunoassay
perform
poorli
adequ
valid
microimmunofluoresc
test
remain
endors
approach
primari
infect
igm
antibodi
appear
week
ill
onset
igg
antibodi
may
reach
diagnost
high
titer
week
onset
ill
therefor
confirm
primari
acut
infect
requir
document
igm
titer
greater
rise
igg
titer
acut
convalesc
serum
specimen
case
reinfect
igm
antibodi
may
appear
level
igg
antibodi
titer
may
rise
quickli
within
week
infect
igg
titer
greater
consist
previou
exposur
seen
approxim
half
adult
therefor
singl
elev
igg
titer
confirm
diagnosi
c
pneumonia
infect
organ
dna
directli
identifi
mean
cultur
pcr
test
specimen
nasopharyng
throat
swab
sputum
blood
tissu
publish
pcr
assay
met
valid
criteria
propos
cdc
lcdc
summari
wide
avail
time
test
exist
diagnosi
c
pneumonia
infect
complet
blood
cell
count
result
complet
blood
cell
count
wbc
differenti
may
influenc
therapi
ill
children
addit
evalu
wbc
presenc
anemia
thrombocytopenia
may
guid
subsequ
therapeut
intervent
rais
concern
hemolyticurem
syndrom
rare
complic
pneumococc
pneumonia
specif
wbc
count
make
diagnosi
bacteri
pneumonia
poor
although
wbc
count
elev
mani
children
bacteri
pneumonia
degre
elev
reliabl
distinguish
bacteri
viral
infect
radiograph
infiltr
detect
children
present
medic
care
fever
leukocytosi
absenc
clinic
sign
lrti
relev
find
occult
pneumonia
clear
occult
pneumonia
address
evid
summari
recommend
acutephas
reactant
acutephas
reactant
includ
peripher
wbc
count
differenti
analysi
esr
crp
procalcitonin
reliabl
distinguish
bacteri
viral
infect
use
sole
diagnost
test
korppi
et
al
found
wbc
count
crp
esr
significantli
higher
children
pneumococc
pneumonia
viral
atyp
pneumonia
howev
number
patient
pneumococc
diseas
diagnos
often
serolog
rel
small
n
consider
overlap
valu
group
sensit
posit
predict
valu
specifi
wbc
count
criteria
pneumonia
low
sensit
crp
mgdl
esr
mmh
respect
increas
result
combin
posit
predict
valu
crp
mgdl
esr
mmh
respect
finnish
investig
found
wide
variat
wbc
count
crp
esr
valu
children
cap
attribut
bacteria
virus
valu
differ
significantli
group
procalcitonin
although
promis
sensit
marker
seriou
bacteri
infect
limit
valu
distinguish
nonseri
bacteri
viral
pneumonia
children
valu
wide
distribut
elev
procalcitonin
concentr
children
document
viral
infect
rais
possibl
children
identifi
viral
pneumonia
may
actual
viralbacteri
coinfect
howev
low
valu
may
help
distinguish
viral
pneumonia
bacteri
pneumonia
associ
bacteremia
acutephas
reactant
also
measur
baselin
patient
requir
hospit
declin
valu
crp
procalcitonin
may
correl
improv
clinic
symptom
thu
potenti
serv
object
measur
diseas
resolut
puls
oximetri
hypoxemia
well
establish
risk
factor
poor
outcom
children
infant
system
diseas
especi
respiratori
diseas
criteria
associ
hypoxemia
includ
provid
tabl
oxygen
satur
measur
provid
simpl
reliabl
noninvas
estim
arteri
oxygen
evid
support
routin
use
puls
oximetri
measur
discuss
evid
summari
recommend
initi
chest
radiograph
chest
radiograph
reliabl
distinguish
viral
bacteri
cap
reliabl
distinguish
among
variou
possibl
bacteri
pathogen
therefor
chest
radiograph
substanti
impact
clinic
outcom
addit
may
impract
obtain
chest
radiograph
especi
offic
set
studi
document
chest
radiograph
perform
children
suspect
acut
lrti
led
chang
diagnosi
use
antibiot
children
evalu
clinic
emerg
depart
set
rare
affect
decis
regard
hospit
chest
radiograph
studi
least
use
inform
histori
clinic
examin
consist
diagnosi
pneumonia
suggest
chest
radiograph
necessari
outpati
diagnosi
cap
strongli
suspect
basi
clinic
find
studi
util
chest
radiograph
alario
colleagu
studi
children
month
year
age
fever
respiratori
symptom
resid
order
chest
radiograph
outpati
set
chest
radiograph
obtain
clinic
assess
perform
manag
plan
record
experienc
attend
physician
experienc
physician
chest
radiograph
support
diagnosi
pneumonia
patient
preradiograph
diagnosi
pneumonia
diagnosi
viral
bacteri
pneumonia
made
anoth
patient
preradiograph
diagnosi
lrti
data
develop
countri
also
suggest
chang
manag
result
chest
radiograph
outpati
set
typic
associ
improv
clinic
outcom
radiograph
infiltr
report
children
fever
absenc
tachypnea
hypoxemia
respiratori
distress
sign
lrti
phenomenon
refer
occult
pneumonia
proport
children
year
old
occult
pneumonia
decreas
recommend
univers
vaccin
clinic
featur
associ
higher
likelihood
occult
pneumonia
includ
presenc
cough
fever
day
fever
leukocytosi
wbc
count
outcom
data
absenc
antibiot
therapi
avail
patient
make
relev
occult
pneumonia
diagnosi
uncertain
chest
radiographi
though
routin
requir
perform
patient
prolong
fever
cough
even
absenc
tachypnea
respiratori
distress
rate
radiograph
confirm
pneumonia
among
children
wheez
low
overal
particularli
absenc
fever
among
children
fever
context
wheez
radiograph
infiltr
detect
without
hypoxemia
hypoxemia
defin
percutan
oxygen
satur
therefor
chest
radiographi
diagnosi
pneumonia
routin
recommend
patient
wheez
absenc
fever
hypoxemia
abdomin
pain
occasion
predomin
present
complaint
children
cap
especi
year
age
although
routin
chest
radiograph
necessari
children
abdomin
pain
consid
unexplain
abdomin
pain
especi
context
tachypnea
cough
fever
evalu
chest
radiograph
subject
consequ
variat
even
among
expert
regard
presenc
absenc
radiograph
featur
use
diagnosi
cap
greater
consensu
regard
presenc
alveolar
consolid
compar
radiograph
featur
pneumonia
vaccin
trial
investig
radiolog
work
group
propos
standard
interpret
pediatr
chest
radiograph
diagnosi
pneumonia
standard
includ
report
film
qualiti
classif
specif
find
explicit
statement
regard
radiograph
interpret
high
agreement
identifi
radiograph
confirm
pneumonia
achiev
use
standard
definit
train
kappa
index
radiologist
clinician
review
chest
radiograph
identif
infiltr
chest
radiograph
attend
clinician
compar
radiologist
consist
lead
meaning
differ
clinic
manag
outcom
widespread
adopt
standard
definit
may
facilit
comparison
futur
studi
childhood
pneumonia
followup
chest
radiograph
routin
followup
chest
radiograph
warrant
children
recov
unev
episod
cap
radiolog
abnorm
known
lag
behind
clinic
resolut
followup
chest
radiograph
obtain
week
initi
imag
reveal
persist
residu
abnorm
children
radiograph
confirm
cap
persist
abnorm
like
patient
sign
symptom
pneumonia
time
followup
radiographi
one
studi
howev
abnorm
rare
alter
clinic
manag
studi
systemat
follow
children
radiograph
abnorm
extend
period
time
radiograph
perform
week
episod
radiograph
confirm
cap
reveal
residu
new
chang
children
persist
interstiti
infiltr
interv
develop
atelectasi
commonli
note
find
longterm
followup
year
later
reveal
ill
attribut
initi
episod
cap
prospect
studi
adult
hospit
sever
cap
chest
radiograph
repeat
day
admiss
day
day
patient
respect
still
abnorm
find
delay
resolut
radiograph
abnorm
associ
multilobar
diseas
dull
percuss
examin
higher
crp
level
document
pneumococc
infect
howev
delay
resolut
radiograph
abnorm
portend
failur
antimicrobi
therapi
wors
clinic
outcom
summari
routin
followup
chest
radiograph
provid
addit
clinic
valu
repres
unnecessari
radiat
exposur
infant
children
subset
patient
lobar
collaps
recurr
pneumonia
involv
lobe
may
benefit
repeat
chest
radiographi
patholog
affect
singl
region
relat
obstruct
airway
lumen
region
extrins
compress
airway
intrins
narrow
airway
abnorm
involv
parenchyma
chest
mass
may
appear
repres
pneumonia
imag
detail
discuss
recurr
pneumonia
beyond
scope
document
infecti
etiolog
cap
divers
multipl
common
pathogen
present
spectrum
clinic
diseas
mild
life
threaten
clinician
face
child
sever
manifest
cap
weigh
benefit
diagnost
modal
target
identifi
specif
pathogen
impact
manag
decis
goal
perform
diagnost
test
obtain
evid
caus
pathogen
order
avoid
unnecessari
use
antibiot
provid
optim
pathogendirect
care
child
tracheal
aspir
commonli
obtain
pediatr
icu
suction
specimen
endotrach
tube
use
standard
suction
cathet
specimen
trap
blind
tracheal
aspir
may
adequ
identifi
pathogen
interest
cathet
may
collect
organ
sourc
infect
lung
procur
process
mere
reflect
organ
colon
endotrach
tube
trachea
children
influenza
viru
suspect
etiolog
cap
rapid
pcr
test
pulmonari
secret
obtain
endotrach
tube
may
yield
posit
result
nasopharyng
test
result
neg
bal
provid
quantit
data
pediatr
popul
procedur
complex
patient
small
airway
particularli
neonat
flexibl
bronchoscop
abil
obtain
sampl
suction
port
use
child
without
intub
child
preexist
endotrach
tube
particularli
newer
ultrathin
bronchoscop
gener
flexibl
fiberopt
bronchoscopi
bal
direct
area
concern
well
toler
mechan
ventil
children
bal
procedur
result
signific
reduct
ratio
increas
advers
effect
blood
ph
arteri
carbon
dioxid
pressur
barzohar
sivan
seri
ventil
children
blind
tracheal
aspir
subsequ
bal
recoveri
organ
blind
tracheal
aspir
bal
concord
blind
tracheal
aspir
bal
posit
case
neg
bal
find
aspirateposit
case
patient
organ
isol
ident
techniqu
investig
found
children
antimicrobi
treatment
chang
consequ
cultur
result
bronchoscopi
studi
bal
children
varieti
respiratori
diagnos
tang
chen
found
posit
neg
cultur
result
treatment
chang
patient
prospect
studi
hospit
adult
cap
routin
sputum
cultur
follow
bronchoscopi
protect
specimen
brush
techniqu
bal
within
first
hour
admiss
reveal
bal
sensit
posit
convent
sputum
cultur
posit
protect
specimen
brush
cultur
posit
bal
cultur
advantag
use
invas
techniqu
bronchoscop
protect
specimen
brush
bal
quantit
microbiolog
studi
document
fagon
et
al
prospect
random
studi
includ
ventil
adult
demonstr
decreas
usag
antibiot
lower
mortal
rate
enhanc
cultur
data
invas
techniqu
allow
pathogenspecif
therapi
invas
techniqu
decreas
number
case
treat
incorrectli
tracheal
colon
thu
allow
judici
use
antimicrobi
standard
protect
specimen
brush
techniqu
bronchoscop
routin
use
ventil
children
requir
larger
bronchoscop
thu
larger
endotrach
tube
howev
blind
protect
bal
provid
qualit
quantit
cultur
children
gauvin
et
al
report
techniqu
ventil
children
reproduc
easi
perform
bedsid
yet
complic
frequent
major
complic
minor
transitori
though
signific
advers
event
report
pneumothorax
requir
chest
tube
increas
intracrani
pressur
similar
techniqu
use
infant
young
day
involv
blindli
insert
doublesheath
protect
specimen
brush
point
beyond
endotrach
tube
tip
inner
cathet
extend
cm
protect
plug
expel
allow
brush
advanc
anoth
cm
retract
sheath
remov
techniqu
obtain
definit
cultur
includ
percutan
needl
aspir
affect
lung
area
vuoriholopainen
studi
finnish
children
cap
use
aspir
bedsid
patient
analysi
aspir
sampl
provid
definit
diagnosi
patient
total
bacteria
virus
identifi
patient
return
fluid
adequ
sampl
obtain
pathogen
detect
eighteen
percent
children
evid
pneumothorax
postprocedur
radiograph
although
none
requir
chest
tube
placement
show
resolut
day
imag
ct
ultrasound
percutan
needl
aspir
present
anoth
option
direct
cultur
infect
lung
tissu
final
children
lifethreaten
cap
unknown
etiolog
open
thoracoscop
lung
biopsi
use
though
highrisk
diagnost
procedur
retrospect
review
children
undergo
open
lung
biopsi
demonstr
open
lung
biopsi
led
pertin
chang
clinic
manag
case
open
lung
biopsi
provid
infecti
diagnosi
preced
bal
inadequ
note
open
lung
biopsi
associ
complic
rate
therebi
limit
use
critic
situat
outpati
inpati
empir
oral
antimicrobi
therapi
outpati
design
provid
effect
treatment
bacteri
pathogen
like
caus
lrti
particular
emphasi
pneumonia
common
bacteri
pathogen
one
untreat
treat
inadequ
may
lead
seriou
sequela
much
less
common
lower
respiratori
tract
pathogen
nontyp
strain
h
influenza
routin
requir
empir
therapi
concern
lrti
caus
aureu
includ
camrsa
inpati
manag
initi
parenter
therapi
may
minim
morbid
mortal
rate
bacterialvir
coinfect
well
document
occur
influenza
viru
pneumonia
aureu
methicillinsuscept
methicillinresist
strain
group
streptococcu
children
empir
therapi
may
requir
antimicrobi
antivir
agent
streptococcu
pneumonia
treatment
pneumococc
infect
penicillin
g
repres
narrowspectrum
effect
antimicrobi
agent
interpret
vitro
test
suscept
penicillin
revis
recent
knowledg
higher
dose
parenter
administ
penicillin
achiev
tissu
concentr
effect
organ
minimum
inhibitori
concentr
mic
may
effect
strain
mic
like
effect
mic
howev
clear
limit
abil
absorb
oral
administ
penicillin
salt
gastrointestin
tract
chang
interpret
mic
valu
pneumococci
treat
oral
therapi
penicillinsuscept
strain
remain
defin
mic
intermedi
suscept
strain
mic
resist
strain
mic
compar
penicillin
amoxicillin
display
favor
pharmacokinet
toler
respect
oral
therapi
dose
antimicrobi
recommend
effect
treatment
directli
relat
suscept
strain
pneumonia
treat
time
initi
pediatr
registr
trial
amoxicillin
earli
vast
major
isol
highli
suscept
standard
dosag
therapi
mgkgday
divid
equal
dose
appear
uniformli
success
develop
widespread
pneumococc
resist
penicillin
highdosag
amoxicillin
mgkgday
studi
attempt
overcom
resist
pneumococcu
found
success
acut
otiti
media
given
twice
daili
halflif
amoxicillin
middl
ear
fluid
document
hour
compar
hour
serum
provid
support
evid
twicedaili
dose
acut
otiti
media
similar
prospect
compar
data
support
recommend
twicedaili
dose
collect
document
pneumococc
pneumonia
children
achiev
appropri
amoxicillin
exposur
lung
infect
rel
resist
pneumococci
mic
high
total
daili
dose
mgkgday
equal
divid
portion
predict
achiev
clinic
microbiolog
cure
children
treat
compar
children
treat
total
daili
dose
divid
equal
dose
howev
fulli
suscept
strain
dosag
mgkgday
divid
portion
indic
otiti
media
like
success
success
pneumococc
vaccin
decreas
invas
pneumococc
infect
decreas
degre
penicillin
resist
circul
strain
document
suggest
appropri
dosag
amoxicillin
may
decreas
recommend
prevaccin
era
howev
emerg
antibioticresist
serotyp
strain
pneumococcu
expert
believ
pneumococc
pneumonia
suspect
oral
therapi
appropri
highdosag
amoxicillin
still
prefer
although
serotyp
includ
newer
pneumococc
vaccin
soon
evalu
impact
intervent
invas
diseas
emerg
antibiot
resist
serotyp
although
amoxicillin
broader
spectrum
activ
penicillin
recommend
oral
therapi
pneumonia
caus
pneumonia
owe
better
absorpt
gastrointestin
tract
yield
higher
serum
concentr
abil
treat
less
suscept
organ
longer
serum
halflif
allow
less
frequent
dose
better
tast
toler
young
children
oral
cephalosporin
dose
studi
children
provid
activ
site
infect
equal
highdos
amoxicillin
second
thirdgener
oral
cephalosporin
provid
adequ
activ
current
isol
strain
pneumococcu
clindamycin
provid
vitro
activ
pneumococci
certain
geograph
region
wherea
oral
levofloxacin
linezolid
provid
activ
strain
daili
intramuscular
inject
ceftriaxon
use
outpati
therapi
vitro
activ
document
pneumococci
stepdown
oral
therapi
child
demonstr
clinic
respons
parenter
therapi
signific
macrolid
resist
exist
current
isol
strain
pneumonia
therefor
current
avail
macrolid
erythromycin
azithromycin
clarithromycin
recommend
empir
therapi
pneumococc
cap
suspect
furthermor
azithromycin
prolong
serum
elimin
halflif
prolong
exposur
organ
respiratori
tract
mucosa
associ
select
resist
organ
mucos
surfac
treat
patient
may
repres
sourc
resist
organ
other
commun
children
histori
nonseri
allerg
reaction
amoxicillin
treatment
well
defin
individu
option
includ
trial
amoxicillin
medic
observ
first
dose
trial
oral
cephalosporin
substanti
activ
pneumonia
cefpodoxim
cefprozil
cefuroxim
also
medic
supervis
seriou
allergi
includ
histori
anaphylaxi
treatment
option
includ
respiratori
fluoroquinolon
levofloxacin
linezolid
macrolid
recogn
commun
isol
pneumonia
may
resist
class
antibiot
clindamycin
suscept
children
bacterem
pneumococc
pneumonia
particular
caution
exercis
select
altern
amoxicillin
given
potenti
secondari
site
infect
includ
mening
parenter
therapi
inpati
higher
dosag
also
use
treatment
nonsuscept
strain
pneumococcu
use
treatment
fulli
suscept
strain
region
highlevel
penicillin
resist
mic
among
invas
strain
substanti
higher
dose
penicillin
g
ukgday
given
everi
hour
ampicillin
mgkgday
given
everi
hour
may
use
similar
dosag
demonstr
safe
treatment
mening
requir
dose
interv
penicillin
g
frequent
ampicillin
agent
owe
serum
halflif
infant
short
min
altern
therapi
provid
ceftriaxon
cefotaxim
standard
nonmening
dosag
document
effect
adult
cap
caus
strain
previous
consid
resist
ceftriaxon
ceftriaxon
cefotaxim
substanti
activ
vitro
penicillinresist
strain
penicillin
g
microbiolog
failur
ceftriaxon
report
children
pneumococc
pneumonia
organ
demonstr
ceftriaxon
mic
publish
data
adult
support
use
ceftriaxon
organ
mic
ceftriaxon
caution
exercis
treat
resist
pneumococci
parenter
cephalosporin
prospect
collect
data
exist
document
efficaci
although
prospect
evalu
intraven
ampicillin
amoxicillin
compar
ceftriaxon
conduct
children
limit
data
adult
suggest
intraven
amoxicillin
amoxicillin
clavulan
avail
unit
state
effect
ceftriaxon
strain
demonstr
amoxicillin
mic
cost
penicillin
ampicillin
less
antimicrobi
agent
util
hospit
resourc
overal
cost
administr
agent
given
everi
hour
may
greater
agent
given
twice
daili
lower
cost
hospit
care
howev
need
balanc
increas
possibl
alter
normal
microbiom
emerg
resist
may
occur
agent
greater
broadspectrum
activ
penicillin
g
children
initi
treat
broadspectrum
antimicrobi
adequ
cultur
either
obtain
obtain
antimicrobi
treatment
begun
document
pathogen
transit
oral
therapi
amoxicillin
still
appropri
respect
decis
regard
select
parenter
versu
oral
empir
therapi
cap
prospect
data
exist
specif
address
issu
widespread
use
pneumococc
conjug
vaccin
retrospect
review
children
pneumococc
bacteremia
document
among
children
pneumonia
receiv
initi
parenter
antibiot
therapi
emerg
depart
discharg
like
clinic
improv
includ
lower
magnitud
fever
less
like
requir
subsequ
hospit
receiv
oral
antibiot
therapi
relev
find
current
manag
unclear
particularli
widespread
use
pneumococc
conjug
vaccin
find
suggest
parenter
therapi
may
associ
rapid
respons
haemophilu
influenza
univers
recommend
h
influenza
type
b
conjug
vaccin
past
year
virtual
elimin
pathogen
children
therefor
consid
routin
pathogen
cap
nontyp
h
influenza
usual
consid
pathogen
pediatr
pneumonia
except
chronic
lung
diseas
chronic
obstruct
develop
isol
thought
true
pathogen
pediatr
cap
oral
amoxicillin
effect
therapi
mild
moder
infect
caus
strain
organ
caus
lrti
amoxicillin
clavulan
secondgener
cefuroxim
thirdgener
cefdinir
cefixim
cefpodoxim
ceftibuten
oral
cephalosporin
effect
therapi
fluoroquinolon
usual
need
treatment
h
influenza
infect
children
except
sever
allerg
oral
agent
inpati
therapi
ampicillin
activ
virtual
strain
north
america
wherea
secondgener
cefuroxim
thirdgener
ceftriaxon
cefotaxim
cephalosporin
activ
strain
group
streptococcu
streptococcu
pyogen
group
streptococcu
remain
infrequ
caus
pediatr
cap
may
caus
sever
necrot
pneumonia
penicillin
cephalosporin
resist
describ
pathogen
clindamycin
resist
rare
geograph
area
inpati
penicillin
g
may
use
treat
diseas
dosag
ukgday
divid
dose
although
dosag
high
ukgday
welltoler
may
use
sever
diseas
macrolid
consid
antimicrobi
choic
treatment
streptococc
infect
compar
antibiot
resist
macrolid
greater
erythromycin
tissu
concentr
toler
lower
children
manifest
toxinmedi
diseas
toxic
syndrom
expert
recommend
combin
therapi
clindamycin
decreas
sever
symptom
believ
caus
streptococc
toxin
staphylococcu
aureu
pneumonia
suspect
caus
aureu
often
treat
initi
inpati
set
multipl
strain
clone
aureu
differ
suscept
pattern
current
circul
unit
state
inpati
infect
caus
methicillinsuscept
aureu
mssa
singl
drug
intraven
therapi
penicillin
oxacillin
nafcillin
firstgener
cephalosporin
cefazolin
adequ
combin
therapi
aminoglycosid
gentamicin
well
studi
although
sever
infect
combin
use
expert
particularli
first
day
therapi
clinic
respons
achiev
similarli
combin
therapi
rifampin
support
part
vitro
data
mani
strain
may
use
sever
infect
howev
aminoglycosid
prospect
collect
wellcontrol
clinic
data
exist
combin
therapi
rifampin
camrsa
increas
problem
mani
area
unit
state
compris
clinic
isol
region
virtual
strain
camrsa
isol
children
suscept
vancomycin
bactericid
agent
consid
drug
choic
seriou
infect
intraven
clindamycin
altern
agent
mssa
mrsa
suscept
strain
knowledg
local
resist
rate
laboratori
document
suscept
guid
therapi
seriou
infect
induc
resist
clindamycin
may
present
staphylococci
ie
may
dtest
posit
strain
clindamycin
use
highinoculum
infect
empyema
risk
presenc
organ
constitut
produc
methylas
high
expert
use
clindamycin
ribosomaltarget
antibiot
manifest
toxinmedi
infect
present
data
prospect
control
studi
collect
date
expert
use
gentamicin
clindamycin
rifampin
combin
vancomycin
treatment
lifethreaten
infect
caus
camrsa
although
prospect
collect
data
exist
support
practic
virtual
strain
camrsa
also
suscept
linezolid
bacteriostat
agent
current
consid
secondlin
therapi
linezolid
may
advantag
patient
preexist
renal
dysfunct
receiv
nephrotox
agent
daptomycin
inactiv
pulmonari
surfact
indic
treatment
staphylococc
pneumonia
despit
laboratori
report
may
document
suscept
children
sever
type
hypersensit
drug
toler
vancomycin
clindamycin
treat
linezolid
although
antibiot
rel
high
advers
effect
profil
platelet
neutrophil
suppress
peripher
nerv
injuri
occur
frequent
document
antibiot
although
advers
effect
occur
end
second
week
therapi
atyp
pneumonia
mycoplasma
pneumonia
symptomat
lrti
associ
pathogen
best
describ
schoolag
children
adult
howev
prospect
random
blind
placebocontrol
clinic
trial
perform
specif
mycoplasma
lrti
children
studi
cap
children
collect
inform
mycoplasma
retrospect
prospect
enrol
insuffici
number
children
infect
document
caus
mycoplasma
allow
statist
valid
conclus
regard
benefit
antibiot
recent
emerg
macrolideresist
pneumonia
japan
provid
opportun
compar
clinic
outcom
children
treat
macrolid
note
retrospect
infect
either
macrolidesuscept
ms
strain
n
mean
age
year
macrolideresist
mr
strain
n
mean
age
year
base
organ
cultur
assess
resist
microdilut
techniqu
pcr
identif
mutat
previous
link
macrolid
resist
retrospect
analysi
compar
children
infect
ms
versu
mr
strain
day
fever
vs
day
cough
vs
day
significantli
decreas
infect
ms
strain
p
data
extrapol
adult
studi
suggest
modest
benefit
therapi
tetracyclin
macrolid
ill
mild
moder
sever
like
children
moder
sever
diseas
benefit
treatment
macrolid
tetracyclin
children
year
therapi
respiratori
fluoroquinolon
demonstr
treatment
outcom
adult
inferior
macrolid
tetracyclin
note
preschool
children
mycoplasma
lrti
document
serolog
amoxicillin
clavulan
demonstr
clinic
outcom
equival
levofloxacin
evalu
primari
end
point
clinic
cure
testofcur
visit
day
last
dose
studi
drug
result
suggest
high
rate
spontan
clinic
resolut
mycoplasma
infect
without
need
antimicrobi
therapi
younger
age
group
although
lack
benefit
may
result
analysi
testofcur
visit
without
addit
analysi
benefit
much
earlier
time
point
therapi
chlamydia
trachomati
c
pneumonia
chlamydia
trachomati
often
identifi
caus
afebril
lrti
young
infant
week
age
born
mother
genit
infect
wherea
c
pneumonia
believ
caus
atyp
pneumonia
schoolag
children
adolesc
antimicrobi
treatment
effect
c
pneumonia
lrti
older
children
difficult
defin
serolog
method
diagnosi
well
standard
correl
cultur
posit
serolog
posit
poor
children
cultur
treat
macrolid
erad
rate
similar
rate
clinic
improv
occur
persist
cultur
posit
demonstr
appar
microbiolog
cure
influenza
antivir
therapi
exist
suscept
strain
influenza
adamantan
neuraminidas
inhibitor
suscept
strain
influenza
b
neuraminidas
inhibitor
substanti
genet
variat
occur
influenza
year
year
resist
influenza
viru
strain
either
class
antivir
agent
may
develop
spread
quickli
major
strain
influenza
viru
isol
sinc
season
adamantin
resist
resist
adamantan
intrins
influenza
b
strain
cdc
track
report
resist
strain
analyz
influenza
season
dosag
antivir
agent
current
recommend
season
influenza
develop
fulli
suscept
strain
evalu
clinic
trial
mandat
treatment
within
hour
onset
symptom
although
earlier
treatment
result
benefit
patient
seriou
ill
ongo
clinic
deterior
hour
symptom
still
like
benefit
therapi
degre
benefit
defin
situat
optim
dose
oseltamivir
known
patient
sever
ill
highli
pathogen
avian
influenza
infect
receiv
extracorpor
membran
oxygen
sever
immun
defici
transplant
recipi
expert
suggest
higher
dose
eg
mg
administ
oral
everi
hour
person
kg
howev
prospect
control
data
exist
base
higher
dosag
durat
therapi
beyond
standard
treatment
cours
investig
neuroaminidas
inhibitor
administ
intraven
avail
treatment
document
infect
pandem
adequ
data
safeti
efficaci
antivir
agent
particularli
children
yet
avail
complet
inform
antivir
therapi
avail
idsa
guidelin
influenza
note
throughout
guidelin
bacterialvir
coinfect
welldocu
occur
influenza
viru
often
document
pneumonia
aureu
methicillinsuscept
methicillinresist
strain
group
streptococcu
investig
bacteri
infect
may
still
import
child
seriou
viral
lrti
empir
therapi
bacteri
agent
may
also
necessari
respiratori
syncyti
viru
controversi
exist
regard
efficaci
inhal
ribavirin
treatment
rsv
cap
infant
ribavirin
vitro
activ
rsv
use
drug
rsv
infect
routin
recommend
manag
lower
respiratori
tract
diseas
owe
consider
cost
aerosol
administr
potenti
toxic
effect
among
expos
healthcar
provid
efficaci
effect
prophylaxi
rsv
infect
avail
palivizumab
synagi
human
murin
monoclon
antibodi
administ
intramuscularli
recommend
target
popul
prophylaxi
dosag
durat
prophylaxi
avail
aap
investig
monoclon
antibodi
rsv
potent
palivizumab
shown
promis
prophylaxi
rsv
infect
parainfluenza
viru
adenoviru
metapneumoviru
rhinoviru
coronaviru
bocaviru
data
prospect
control
studi
antivir
therapi
virus
associ
pediatr
cap
evid
support
impact
decreas
antibiot
use
emerg
multidrug
resist
organ
hospit
avail
number
recent
review
antimicrobi
stewardship
program
although
mani
inpati
program
demonstr
antibiot
use
decreas
shown
decreas
use
specif
antibiot
lead
decreas
isol
organ
resist
particular
antibiot
institut
furthermor
analys
assess
reduct
actual
number
patient
infect
caus
organ
resist
specif
antibiot
reduct
use
specif
antibiot
even
fewer
highqual
data
avail
pediatr
infect
treat
outpati
basi
evid
support
use
lowest
effect
antimicrobi
drug
exposur
dose
durat
requir
prevent
emerg
resist
subsequ
infect
antibiot
resist
organ
yet
evalu
publish
durat
antimicrobi
therapi
children
develop
world
primarili
studi
context
antibiot
registr
trial
compar
newer
agent
standard
treatment
cours
day
day
azithromycin
distinctli
differ
tissuesit
pharmacokinet
compar
antibiot
protocol
shortcours
therapi
studi
develop
world
clinic
laboratori
radiograph
descript
studi
patient
less
definit
develop
countri
document
bacteri
pathogen
infrequ
similar
prospect
compar
studi
shortcours
therapi
intens
investig
etiolog
pneumonia
perform
develop
world
although
total
cours
therapi
often
day
transit
oral
therapi
often
use
allow
discharg
inpati
set
provid
decreas
risk
intraven
administr
therapi
exposur
nosocomi
pathogen
although
data
prospect
control
studi
avail
retrospect
review
suggest
practic
effect
transit
intraven
daili
intramuscular
therapi
longact
antibiot
particularli
ceftriaxon
ertapenem
may
provid
anoth
option
hospit
discharg
child
longer
requir
supplement
oxygen
skill
nurs
care
may
still
requir
parenter
therapi
area
skill
pediatr
outpati
nurs
resourc
children
may
requir
longer
durat
parenter
therapi
outpati
intraven
therapi
indwel
central
cathet
daili
skill
pediatr
home
nurs
visit
provid
anoth
option
outofhospit
care
durat
parenter
therapi
transit
oral
therapi
base
sever
initi
present
rapid
improv
improv
fever
cough
tachypnea
supplement
oxygen
depend
increas
activ
appetit
support
reduct
peripher
leukocyt
count
andor
crp
acutephas
reactant
use
mani
clinician
aid
decis
regard
transit
oral
therapi
absenc
bacteremia
children
bacteremia
secondari
foci
infect
found
transit
oral
therapi
take
place
earli
day
start
parenter
therapi
although
data
support
recommend
primarili
retrospect
addit
amoxicillin
oral
antibiot
option
avail
allerg
child
depend
antimicrobi
suscept
pathogen
certain
antimicrobi
drug
demonstr
excel
absorpt
gastrointestin
tract
deem
appropri
therapi
like
effect
mouth
parenter
rout
convalesc
child
compliant
famili
antimicrobi
includ
fluoroquinolon
linezolid
clindamycin
trimethoprimsulfamethoxazol
azithromycin
infect
caus
certain
pathogen
notabl
camrsa
may
requir
longer
treatment
caus
pneumonia
complic
infect
result
parapneumon
effus
empyema
lung
abscess
may
also
requir
therapi
day
prospect
random
trial
defin
durat
base
attribut
pathogen
characterist
pneumonia
perform
expert
would
treat
appropri
drain
effus
empyema
day
resolut
fever
wherea
other
recommend
therapi
week
lung
abscess
vari
size
microbi
etiolog
therapi
individu
base
clinic
laboratori
imag
respons
antimicrobi
treatment
clinic
sign
symptom
includ
fever
respiratori
rate
oxygen
measur
puls
oximetri
supplement
oxygen
requir
demonstr
improv
within
hour
base
data
origin
collect
year
ago
placebocontrol
trial
antimicrobi
therapi
first
becam
avail
clinic
find
respons
therapi
may
support
laboratori
marker
inflamm
certain
acutephas
reactant
procalcitonin
crp
although
laboratori
test
routin
incorpor
clinic
trial
design
adequ
evalu
valid
discuss
manag
children
provid
evid
summari
recommend
parapneumon
effus
defin
collect
fluid
pleural
space
associ
underli
pneumonia
larg
studi
patient
cap
canada
parapneumon
effus
observ
adult
patient
children
prospect
studi
cap
europ
america
demonstr
parapneumon
effus
parapneumon
effus
may
occur
pneumonia
due
pneumonia
may
also
seen
viral
pneumonia
effus
rare
larg
enough
requir
intervent
parapneumon
effus
occur
frequent
bacteri
pneumonia
occur
case
due
typic
bacteria
includ
pneumonia
pyogen
aureu
countri
h
influenza
type
b
vaccin
gener
use
parapneumon
empyema
collect
pu
pleural
space
associ
underli
pneumonia
pu
may
defin
gross
appear
wbc
count
posit
bacteri
cultur
hospit
rate
parapneumon
empyema
increas
unit
state
children
cap
parapneumon
effus
may
suspect
base
histori
physic
examin
children
cap
prolong
fever
chest
pain
abdomin
pain
associ
parapneumon
effus
physic
examin
may
reveal
sign
pleural
fluid
includ
dull
percuss
diminish
breath
sound
chang
qualiti
breath
sound
transmit
speech
effus
chest
radiographi
includ
later
decubitu
view
use
confirm
presenc
pleural
fluid
children
cap
still
question
pleural
fluid
versu
parenchym
opacif
imag
chest
ultrasound
ct
scan
warrant
chest
ultrasound
consid
safer
imag
procedur
ct
owe
lack
ioniz
radiat
drainag
parapneumon
effus
may
requir
sever
reason
common
caus
parapneumon
effus
children
infect
doubt
infecti
etiolog
effus
malign
suspect
thoracentesi
may
perform
cytolog
examin
empyema
present
drainag
purul
materi
usual
requir
adequ
treatment
infect
drainag
infect
pleural
fluid
may
result
decreas
fever
inflamm
hospit
stay
final
size
effus
degre
respiratori
compromis
import
factor
consid
determin
manag
plan
small
effus
see
tabl
often
respond
well
antibiot
therapi
usual
requir
intervent
moder
larg
effus
like
caus
respiratori
compromis
resolv
quickli
benefit
drainag
outlin
figur
although
classif
effus
size
qualit
arbitrari
effus
size
classif
criteria
use
guidelin
similar
recommend
adult
patient
also
use
least
recent
investig
small
effus
mm
rim
fluid
later
decubitu
less
onefourth
hemithorax
opacifi
upright
chest
radiograph
like
resolv
usual
requir
drainag
report
singleinstitut
retrospect
experi
pneumonia
parapneumon
effus
carter
et
al
note
small
pleural
effus
requir
drainag
patient
small
effus
recov
unev
antibiot
therapi
alon
absenc
mediastin
shift
patient
moder
pleural
effus
requir
drainag
carter
et
al
also
note
children
larg
effus
half
hemithorax
opacifi
ultim
requir
pleural
drainag
adult
ferguson
et
al
note
simpl
aspir
drainag
like
fail
effus
occupi
hemithorax
also
consensu
british
thorac
societi
guidelin
children
adultbas
american
colleg
chest
physician
consensu
statement
data
concern
moder
effus
although
carter
et
al
note
major
children
moder
effus
success
manag
without
pleural
drainag
child
treat
initi
antibiot
alon
requir
readmiss
pleural
fluid
drainag
howev
prospect
studi
need
area
effus
larg
enough
warrant
consider
drainag
presenc
locul
organ
fluid
influenc
treatment
decis
drainag
chest
thoracostomi
tube
alon
may
effect
adjunct
therapi
may
requir
choic
adjunct
therapi
discuss
imag
studi
choic
assess
pleural
fluid
locul
chest
ultrasound
although
later
decubitu
radiographi
ct
chest
also
use
evid
locul
parapneumon
effus
associ
complic
hospit
cours
ramnath
et
al
found
children
locul
parapneumon
effus
treat
antibiot
alon
either
without
chest
tube
placement
longer
length
stay
complic
cours
simpl
nonlocul
effus
treat
similarli
himelman
et
al
note
adult
locul
parapneumon
effus
larger
effus
longer
hospit
stay
underw
thoracostomi
procedur
frequent
nonlocul
effus
howev
carter
et
al
found
pleural
fluid
locul
associ
need
pleural
drainag
gram
stain
bacteri
cultur
pleural
fluid
posit
case
pneumonia
complic
parapneumon
effus
investig
report
posit
cultur
posit
pleural
fluid
cultur
direct
antibiot
therapi
unfortun
major
parapneumon
effus
although
thought
caus
pathogen
bacteria
cultur
neg
use
nucleic
acid
antigen
detect
method
sever
studi
unit
state
europ
demonstr
cultureneg
empyema
caus
primarili
pneumonia
often
nonvaccin
serotyp
suscept
penicillin
method
greater
sensit
tradit
culturebas
method
identifi
bacteri
pathogen
sampl
especi
patient
pretreat
antibiot
antigen
nucleic
acid
assay
diagnosi
pathogen
respons
parapneumon
empyema
includ
pneumonia
aureu
still
develop
test
may
help
center
avail
test
current
fdaapprov
mani
develop
may
wish
seek
full
fda
approv
use
neonat
infant
children
base
econom
medic
ethic
concern
biochem
test
pleural
fluid
often
perform
adult
distinguish
exud
transud
effus
help
guid
clinic
manag
children
overwhelm
major
parapneumon
effus
due
infect
biochem
test
rare
requir
help
establish
etiolog
eg
infect
vs
malign
caus
effus
rare
associ
chang
patient
manag
adult
patient
metaanalysi
demonstr
ph
highest
diagnost
accuraci
identifi
complic
parapneumon
effus
requir
pleural
fluid
drainag
area
receiv
oper
characterist
roc
curv
compar
pleural
fluid
glucos
lactat
dehydrogenas
even
exclus
pleural
fluid
grossli
purul
ph
retain
high
diagnost
accuraci
area
roc
curv
decis
threshold
ph
cutoff
valu
children
ph
valu
associ
need
pleural
fluid
drainag
biochem
test
pleural
fluid
children
parapneumon
effus
associ
pneumonia
requir
howev
expert
believ
measur
pleural
fluid
ph
obtain
time
initi
drainag
may
help
guid
decis
regard
need
pleural
fluid
drainag
wbc
count
differenti
analysi
convent
perform
pleural
fluid
valu
analysi
demonstr
bacteri
etiolog
replac
molecular
analysi
valu
pleural
fluid
cell
count
predict
morbid
outcom
justifi
strong
recommend
howev
clue
origin
pleural
fluid
caus
less
common
etiolog
tuberculosi
malign
may
found
cell
count
differenti
analysi
cytolog
find
fluid
choic
drainag
procedur
depend
local
region
expertis
experi
patient
pleural
fluid
locul
initi
drainag
chest
tube
alon
option
though
proceed
directli
adjunct
therapi
also
reason
locul
effus
drain
chest
tube
alon
thu
requir
adjunct
therapi
chest
tube
drainag
instil
fibrinolyt
agent
includ
urokinas
tissu
plasminogen
activ
vat
advoc
effect
treatment
measur
pediatr
parapneumon
effus
either
chest
tube
drainag
fibrinolysi
vat
prefer
chest
tube
drainag
alon
complic
locul
effus
current
avail
data
adequ
determin
one
procedur
clearli
prefer
see
tabl
fibrinolyt
regimen
use
children
intervent
report
improv
patient
outcom
includ
resolut
infect
decreas
length
hospit
stay
compar
conserv
treatment
chest
tube
drainag
antibiot
two
singlecent
random
control
trial
compar
fibrinolyt
therapi
vat
although
differ
strategi
fibrinolysi
use
sonnappa
et
al
patient
treat
urokinas
vat
st
peter
et
al
patient
treat
alteplas
treat
vat
studi
demonstr
similar
patient
outcom
includ
length
hospit
stay
also
demonstr
decreas
cost
treatment
parapneumon
empyema
fibrinolyt
agent
compar
vat
random
trial
kurt
et
al
patient
treat
vat
treat
convent
tube
thoracostomi
reteplas
fibrinolysi
sole
rescu
therapi
document
shorter
length
stay
among
patient
undergo
initi
vat
base
current
avail
data
chest
tube
fibrinolysi
vat
consid
accept
initi
drainag
strategi
approxim
children
parapneumon
effus
treat
fibrinolyt
agent
via
chest
tube
requir
intervent
complet
drainag
pleural
space
children
requir
intervent
vat
open
thoracotomi
decort
persist
moder
larg
effus
ongo
respiratori
compromis
despit
day
manag
chest
tube
fibrinolyt
agent
persist
fever
alon
indic
treatment
failur
chest
ct
perform
evalu
adequaci
pleural
fluid
drainag
determin
whether
locul
fluid
collect
necrot
parenchym
diseas
present
failur
chest
tube
fibrinolyt
agent
drainag
pleural
space
often
accomplish
vat
rare
children
requir
open
decort
routin
necessari
obtain
chest
radiograph
serial
vat
chest
tube
placement
chest
tube
place
either
primari
treatment
vat
criteria
remov
includ
absenc
air
leak
h
pleural
fluid
drainag
usual
calcul
last
hour
ml
total
period
often
accomplish
within
hour
oper
complet
fibrinolysi
antibiot
treatment
parapneumon
effus
empyema
similar
cap
without
effus
bacteri
pathogen
respons
cap
parapneumon
effus
empyema
also
similar
pneumonia
commonli
isol
pathogen
studi
though
aureu
remain
import
caus
empyema
less
common
caus
uncompl
cap
whenev
possibl
antibiot
therapi
pathogen
direct
base
result
bacteri
cultur
either
blood
pleural
fluid
unfortun
pleural
fluid
cultur
often
neg
owe
high
frequenc
antibiot
treatment
initi
fluid
obtain
cultur
circumst
treatment
base
region
epidemiolog
select
provid
coverag
common
pathogen
see
evid
summari
recommend
molecular
test
use
cultureneg
empyema
often
found
due
pneumonia
partial
treat
bacteri
cultur
obtain
rare
found
due
aureu
empyema
caus
aureu
especi
camrsa
result
posit
bacteri
cultur
often
empyema
caus
pneumococcu
singlecent
studi
pleural
fluid
specimen
test
bacteri
cultur
pcr
case
camrsa
demonstr
cultur
pcr
case
mrsa
demonstr
pcr
cultur
neg
pleural
fluid
although
find
verifi
set
higher
incid
camrsa
optim
durat
antibiot
treatment
parapneumon
effus
empyema
depend
adequaci
drainag
procedur
may
vari
pathogen
determin
random
control
trial
treatment
week
commonli
recommend
expert
treat
infect
day
resolut
fever
decis
consid
patient
nonrespond
therapi
bacteri
viral
cap
base
clinician
interpret
patient
clinic
cours
time
laboratori
data
rel
patient
condit
onset
therapi
gener
clinician
consid
patient
nonrespond
lack
improv
within
hour
signific
worsen
time
initi
therapi
frequenc
nonrespons
pediatr
pneumonia
well
describ
estim
overal
hospit
children
similar
find
metaanalysi
prospect
random
trial
adult
investig
treatment
failur
persist
fever
deterior
patient
condit
requir
chang
prescrib
antibiot
seen
patient
clinic
judgment
paramount
defin
nonrespons
determin
nonrespons
also
influenc
laboratori
andor
imag
result
rel
weight
factor
decis
consid
patient
nonrespond
vari
age
set
outpati
vs
inpati
vs
icu
sever
present
final
rate
clinic
deterior
durat
lack
improv
follow
factor
influenc
decis
consid
patient
nonrespond
hour
children
nonrespond
cap
clinic
sever
condit
repeatedli
assess
determin
whether
requir
higher
level
care
exampl
admiss
hospit
outpati
set
skill
transport
commun
hospit
tertiari
pediatr
care
center
transfer
icu
hospit
ward
evalu
includ
monitor
expect
improv
present
find
may
includ
fever
respiratori
rate
respiratori
distress
chest
retract
grunt
hypoxemia
puls
oximetri
children
also
monitor
global
respons
term
activ
appetit
hydrat
statu
outpati
nonrespond
requir
hospit
see
evid
summari
recommend
unabl
maintain
adequ
oxygen
hydrat
show
sign
increas
work
breath
toxic
children
treat
initi
oral
antibiot
therapi
presum
bacteri
atyp
pneumonia
outpati
may
actual
infect
pathogen
suscept
initi
therapi
may
requir
altern
addit
antibacteri
antivir
therapi
children
nonrespond
cap
moder
sever
undergo
radiograph
imag
particularli
clinic
evid
suggest
increas
respiratori
effort
increas
area
abnorm
lung
sound
dull
percuss
area
detect
previous
outpati
prefer
imag
studi
chest
radiographi
includ
posteroanterior
later
view
moder
larg
pleural
effus
suspect
later
decubitu
chest
radiograph
chest
ultrasound
indic
see
evid
summari
recommend
chest
mass
pulmonari
abscess
necrot
pneumonia
suspect
chest
ct
perform
children
complic
pneumonia
includ
moder
larg
pleural
effus
requir
consult
servic
institut
expertis
obtain
pleural
fluid
specimen
provid
drainag
fibrinolyt
agent
andor
vat
see
evid
summari
recommend
reassess
bacteri
pathogen
may
includ
sputum
cultur
children
cough
expector
children
parapneumon
effus
respond
antimicrobi
therapi
alon
pleural
fluid
sampl
obtain
cultur
gram
stain
avail
either
pcr
antigen
test
sampl
also
evalu
mycobacteria
fungi
appropri
stain
cultur
context
clinic
relev
exposur
clinic
present
children
also
consid
drainag
remov
effus
serious
ill
children
requir
mechan
ventil
cultur
obtain
bronchoscopi
use
bal
tracheal
aspir
bronchial
brush
may
help
although
rare
pathogen
present
cap
cap
children
usual
caus
tradit
respiratori
tract
pathogen
see
etiolog
cap
respond
initi
empir
antimicrobi
therapi
particularli
attempt
discov
pathogen
initi
consid
necessari
aggress
approach
pathogen
identif
furthermor
patient
reassess
consid
whether
resist
common
bacteri
viral
pathogen
unusu
pathogen
includ
fungal
mycobacteri
parasit
organ
may
respons
worsen
sign
symptom
secondari
bacteri
infect
airway
obstruct
either
intrins
extrins
mechan
also
consid
inpati
fail
respond
initi
therapi
may
requir
expans
antimicrobi
therapi
pathogen
includ
spectrum
initi
antibiot
choic
subsequ
display
resist
initi
agent
mean
induct
resist
mechan
mutat
select
small
subpopul
pathogen
intrins
resist
agent
detect
initi
cultur
exampl
patient
initi
treat
intraven
ampicillin
coverag
broaden
either
nafcillinoxacillin
cefazolin
mssa
clindamycin
moder
ill
patient
vancomycin
patient
sever
lifethreaten
condit
mrsa
anoth
exampl
repres
patient
receiv
longterm
treatment
vancomycin
infect
caus
camrsa
select
heteroresist
vancomycin
occur
increas
mic
requir
increas
dosag
vancomycin
achiev
cure
patient
requir
signific
intervent
maintain
adequ
oxygen
perfus
mechan
ventil
cardiovascular
support
extracorpor
membran
oxygen
support
transfer
unit
capabl
provid
intens
care
nonrespond
cap
suspect
either
viral
origin
result
coinfect
bacteri
viral
pathogen
confirm
viral
pathogen
benefici
rapid
antigen
test
pcr
advantag
rapid
turnaround
time
avail
expens
pcr
test
limit
factor
access
molecularbas
technolog
pcr
increas
cost
decreas
test
may
replac
mani
antigenbas
test
gener
improv
test
perform
characterist
identifi
increas
number
viral
pathogen
nonrespond
child
cap
may
influenza
viru
infect
alon
resist
empir
antivir
treatment
oseltamivir
patient
test
oseltamivir
resist
pursu
public
health
laboratori
treatment
initi
altern
antivir
agent
zanamivir
investig
antivir
agent
may
retain
activ
influenza
strain
children
year
old
requir
intraven
antivir
therapi
investig
antivir
therapi
may
requir
usual
drug
manufactur
children
worsen
cap
viral
pathogen
receiv
antivir
treatment
avail
undergo
test
aim
identifi
previous
undetect
bacteri
pathogen
see
evid
summari
recommend
children
present
initi
confirm
viral
cap
occasion
develop
secondari
bacteri
infect
secondari
bacteri
infect
infant
children
viral
diseas
occur
frequent
hospit
children
especi
influenza
rsv
infect
requir
intens
care
secondari
bacteri
infect
suspect
clinic
deterior
support
laboratori
evid
increas
system
inflamm
investig
bacteri
pathogen
warrant
antibacteri
therapi
expand
provid
coverag
common
bacteri
pathogen
keep
mind
local
resist
pattern
occasion
children
year
old
test
mycoplasma
c
pneumonia
warrant
particularli
pulmonari
infiltr
perihilar
bilater
wheez
present
test
result
requir
sever
day
clinician
start
empir
therapi
addit
macrolid
tetracyclin
fluoroquinolon
see
evid
summari
recommend
pulmonari
abscess
aris
previous
normal
lung
result
initi
pneumonia
abscess
andor
lung
necrosi
may
lead
lack
clinic
respons
nonrespond
patient
lesion
chest
radiograph
suggest
abscess
necrot
pneumonia
undergo
ct
chest
contrast
medium
enhanc
help
confirm
rule
process
gener
surgic
intervent
avoid
abscess
resolv
antibiot
alon
howev
abscess
peripher
associ
airway
connect
ctguid
drainag
cathet
placement
reason
option
retrospect
data
suggest
drainag
shorten
hospit
stay
facilit
earlier
recoveri
specimen
obtain
drainag
method
investig
potenti
pathogen
patient
secondari
abscess
due
underli
pulmonari
anomali
lesion
eg
congenit
cystic
adenomatoid
malform
pulmonari
sequestr
requir
surgic
consult
evalu
longterm
manag
lesion
determin
whether
surgic
resect
requir
necrot
pneumonia
treat
medic
surgic
intervent
andor
placement
chest
tube
via
trocar
may
increas
risk
bronchopleur
fistula
studi
clearli
determin
best
criteria
hospit
discharg
howev
follow
criteria
commonli
use
child
decreas
fever
supplement
oxygen
requir
child
take
food
liquid
adequ
least
hour
chest
tube
place
child
free
intrathorac
air
leak
least
hour
tube
remov
adult
improv
pneumonia
primarili
determin
improv
fever
cours
resolut
tachycardia
tachypnea
improv
systol
blood
pressur
resolut
need
supplement
oxygen
assess
puls
oximetri
children
criteria
stabil
cours
treatment
pneumonia
far
less
well
defin
fever
extrem
common
pneumonia
may
persist
sever
day
despit
adequ
therapi
particularli
children
complic
pneumonia
studi
adult
lower
threshold
consid
stabl
temperatur
alter
time
discharg
hospit
impli
least
group
temperatur
stabil
prime
consider
discharg
resolut
fever
sign
adequ
therapi
bacteri
pneumonia
improv
fever
curv
use
document
adequaci
therapi
absenc
definit
organ
sensit
wide
variabl
practic
among
physician
consid
safe
puls
oximetri
level
discharg
patient
pneumonia
howev
use
cutoff
oxygen
supplement
recommend
viral
respiratori
ill
puls
oximetri
measur
fall
acidbas
statu
temperatur
consider
notwithstand
decreas
oxygen
result
faster
declin
satur
rate
determin
oxygendissoci
curv
hemoglobin
infant
children
given
unpleasanttast
antibiot
like
spit
dose
suggest
infant
children
take
liquid
medic
tast
impact
adher
prescrib
therapi
interv
durat
dose
trial
oral
antimicrobi
therapi
discharg
import
particularli
agent
liquid
clindamycin
known
unpalat
tast
way
improv
palat
certain
antibiot
suspens
exist
includ
flavor
avail
home
flavor
ad
time
antibiot
reconstitut
pharmaci
close
followup
primari
care
practition
import
make
sure
child
continu
toler
oral
antimicrobi
therapi
children
complic
pneumonia
often
surgic
procedur
drain
accumul
pleural
fluid
third
patient
primari
chest
tube
placement
may
requir
second
surgic
procedur
fluid
drainag
length
stay
likelihood
reaccumul
fluid
significantli
reduc
elimin
vat
fibrinolyt
therapi
via
chest
tube
see
evid
summari
recommend
howev
care
must
taken
patient
ongo
accumul
pleural
fluid
discharg
may
necessit
conserv
approach
discharg
criteria
patient
receiv
fibrinolyt
therapi
vat
longer
period
observ
accumul
may
warrant
prudent
take
consider
econom
social
condit
impact
complianc
care
safeti
discharg
patient
although
effect
cost
outpati
medic
adher
studi
pediatr
pneumonia
lowincom
parent
less
like
compli
prescrib
medicin
varieti
medic
ill
children
pneumonia
discharg
reason
verifi
patient
prescrib
regimen
well
followup
outpati
servic
care
incur
cost
reduc
likelihood
complianc
one
larg
canadian
studi
children
pneumonia
like
hospit
simpli
lower
socioeconom
statu
presum
poor
time
access
adequ
outpati
servic
anoth
studi
unit
state
children
hospit
cap
came
famili
incom
feder
poverti
threshhold
repres
children
whose
hospit
consid
avoid
outpati
parenter
antimicrobi
therapi
use
success
decad
children
adult
treatment
wide
varieti
infect
includ
pneumonia
lead
creation
idsa
practic
guidelin
outpati
parenter
antimicrobi
therapi
use
set
clinic
paramet
document
need
skill
nurs
care
creation
outpati
manag
consist
pediatrician
skill
pediatr
nurs
pediatr
parenter
therapi
cap
success
varieti
antimicrobi
agent
exampl
infant
children
may
requir
ongo
parenter
therapi
includ
may
ongo
diseas
requir
high
serum
antibiot
concentr
order
achiev
suffici
antibiot
exposur
infect
tissu
includ
extens
parenchym
diseas
parapneumon
effus
lung
abscess
specif
criteria
identifi
children
need
prolong
parenter
therapi
well
defin
random
trial
examin
appropri
oral
compar
parenter
outpati
antibiot
therapi
children
cap
select
oral
antimicrobi
therapi
well
toler
well
absorb
achiev
requir
antimicrobi
exposur
site
infect
essenti
ongo
outpati
treatment
compliant
famili
risk
advers
event
oral
therapi
less
intraven
therapi
earli
retrospect
studi
document
efficaci
oral
stepdown
therapi
children
includ
children
cap
recent
studi
oral
stepdown
therapi
osteomyel
prospect
collect
data
treat
children
demonstr
safeti
effect
oral
outpati
therapi
seriou
bacteri
infect
studi
also
highlight
rel
high
frequenc
complic
peripher
insert
central
venou
cathet
suggest
parenter
outpati
therapi
reserv
children
unabl
toler
either
unabl
take
unabl
absorb
appropri
oral
antibiot
infect
caus
resist
bacteria
appropri
oral
antibiot
unavail
infect
pneumonia
h
influenza
type
b
among
common
caus
pediatr
cap
worldwid
pathogen
account
approxim
half
pneumonia
death
global
children
year
old
infect
pathogen
prevent
immun
unit
state
pneumococc
conjug
h
influenza
type
b
conjug
vaccin
recommend
infant
children
part
routin
infant
immun
schedul
reduc
rate
morbid
mortal
pneumococc
h
influenza
type
b
pneumonia
us
food
drug
administr
approv
pneumococc
conjug
vaccin
cdc
advisori
committe
immun
practic
issu
guidelin
use
immun
children
vaccin
contain
antigen
serotyp
vaccin
serotyp
addit
serotyp
addit
serotyp
report
north
america
south
america
europ
often
implic
pneumonia
especi
pneumonia
complic
empyema
necrosi
licensur
may
decreas
complic
pediatr
pneumonia
empyema
influenza
viru
lrti
children
may
associ
bacteri
pneumonia
without
empyema
immun
inactiv
trival
vaccin
provid
averag
vaccin
efficaci
confid
interv
live
coldadapt
attenu
vaccin
provid
even
greater
efficaci
young
children
month
age
compar
inactiv
trival
vaccin
highest
rate
protect
document
year
vaccin
strain
well
match
circul
strain
influenza
commun
particularli
inactiv
trival
vaccin
children
bacteri
pneumonia
particularli
pneumococc
pneumonia
recent
camrsa
pneumonia
associ
preced
season
influenza
viru
infect
complic
pneumonia
empyema
also
associ
histor
influenza
pandem
pandem
cdc
advisori
committe
immun
practic
aap
current
recommend
univers
annual
influenza
immun
infant
children
age
month
univers
influenza
immun
decreas
pediatr
cap
unit
state
respiratori
syncyti
viru
common
viral
etiolog
hospit
cap
infant
studi
document
abil
palivizumab
synagi
decreas
risk
hospit
due
rsv
diseas
otherwis
healthi
prematur
young
infant
medic
condit
place
greater
risk
hospit
infect
includ
chronic
lung
diseas
prematur
congenit
abnorm
airway
neuromuscular
diseas
guidelin
use
palivizumab
publish
aap
focu
like
benefit
prophylaxi
rsv
season
prematur
infant
comorbid
condit
includ
underli
lung
patholog
congenit
abnorm
airway
hemodynam
signific
congenit
heart
diseas
neuromuscular
diseas
object
outcom
measur
need
guid
decis
surround
initi
site
care
patient
evalu
ambulatori
set
guid
admiss
manag
discharg
decis
hospit
patient
outcom
standard
measur
compar
allow
us
establish
benchmark
care
children
cap
understand
variabl
clinic
cours
pathogen
bacteri
viral
fungal
tuberculosi
coinfect
age
group
socioeconom
group
genet
differ
immun
respons
addit
defin
outcom
measur
current
standard
care
enabl
subsequ
document
benefit
new
therapeut
intervent
relev
outcom
consid
evalu
children
hospit
pneumonia
includ
time
resolut
observ
clinic
vital
sign
abnorm
includ
fever
work
breath
respiratori
rate
tachycardia
need
parenter
fluid
administr
need
surgic
intervent
develop
pneumoniaassoci
local
metastat
system
complic
mortal
addit
outcom
measur
assess
effect
intervent
includ
requir
hospit
length
hospit
readmiss
discharg
cost
care
outcom
consid
studi
childhood
cap
sever
requir
hospit
length
hospit
subject
may
relat
import
nonclin
factor
includ
psychosoci
behavior
consider
socioeconom
consider
potenti
nonadher
prescrib
therapi
barrier
followup
medic
care
other
persist
clinic
symptom
may
relat
nonbacteri
caus
pneumonia
mani
random
trial
adult
hospit
cap
use
mortal
primari
outcom
measur
among
children
mortal
attribut
cap
decreas
past
year
children
hospit
cap
larg
cohort
children
hospit
cap
tertiari
care
children
hospit
children
hospit
cap
die
mortal
rate
examin
studi
childhood
pneumonia
though
infrequ
death
preclud
use
mortal
primari
outcom
measur
unit
state
develop
countri
directli
relat
issu
outcom
measur
childhood
cap
select
initi
site
care
whether
outpati
hospit
decis
import
directli
affect
intens
subsequ
test
therapi
wide
variat
caprel
admiss
rate
neighbor
geograph
region
suggest
physician
use
consist
criteria
make
siteofcar
decis
unnecessari
hospit
disadvantag
includ
nosocomi
infect
exposur
ioniz
radiat
increas
healthcar
cost
howev
outpati
manag
highrisk
patient
may
increas
capassoci
morbid
rate
case
cap
adult
triag
decis
might
facilit
creation
clinic
predict
rule
identifi
patient
high
low
risk
clinic
deterior
pneumoniaassoci
complic
medic
cost
care
child
cap
per
episod
dollar
mean
cost
subset
patient
requir
hospit
per
episod
contribut
famili
burden
parent
day
work
loss
rang
day
cap
treat
ambulatori
set
day
cap
requir
hospit
famili
stress
lead
repercuss
parent
health
famili
moral
cost
consid
primari
outcom
childhood
pneumonia
howev
cost
may
import
factor
choos
among
therapi
similar
efficaci
therefor
studi
examin
compar
effect
differ
treatment
strategi
uncompl
pneumonia
sever
pneumonia
complic
parapneumon
effus
empyema
abscess
necrosi
examin
cost
secondari
outcom
measur
cost
analys
may
also
includ
nonmed
cost
lost
parent
incom
studi
examin
longterm
outcom
children
pneumonia
sever
longitudin
studi
suggest
children
lrti
childhood
higher
risk
subsequ
develop
obstruct
lung
diseas
studi
howev
confirm
diagnosi
pneumonia
chest
radiographi
whether
respiratori
tract
infect
caus
consequ
airway
hyperreact
unclear
among
children
pneumonia
complic
parapneumon
effus
empyema
scoliosi
though
uncommon
may
occur
usual
transient
abnorm
lung
function
common
consist
pattern
abnorm
exist
sampl
size
small
enabl
meaning
comparison
drainag
procedur
lung
function
abnorm
furthermor
children
evalu
lung
function
diagnosi
pneumonia
also
possibl
premorbid
condit
involv
lung
function
exist
pneumonia
assum
investig
result
pneumonia
among
children
complic
pneumonia
evalu
kohn
et
al
mild
restrict
lung
diseas
mild
obstruct
lung
diseas
among
patient
studi
mclaughlin
et
al
year
ago
patient
total
lung
capac
standard
deviat
mean
age
patient
consid
mild
restrict
lung
diseas
defin
total
lung
capac
standard
deviat
mean
age
contrast
patient
studi
red
et
al
year
ago
evid
mild
obstruct
lung
diseas
wherea
lung
function
abnorm
report
among
patient
studi
satish
et
al
year
ago
impact
improv
qualiti
care
provid
pediatr
hospit
medicin
specialist
pediatr
critic
care
specialist
past
decad
like
substanti
remain
poorli
defin
